Tokyo Medical and Dental University Hospital
Welcome,         Profile    Billing    Logout  
 7 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Walters, Thomas
CAMEO, NCT05781152: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

Recruiting
4
900
Canada, US
Anti-TNF therapy, Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio
Connecticut Children's Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Emory University, Children's Hospital Medical Center, Cincinnati, University of North Carolina, Chapel Hill
Crohn Disease
07/28
07/29
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
NCT06164743: Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Completed
2
91
US
VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
VivaVision Biotech, Inc
Inflammation
05/24
05/24
NCT06394973: Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

Active, not recruiting
2
126
US
T4090 0.2%, T4090 0.3%, Rhopressa®
Laboratoires Thea
Glaucoma, Ocular Hypertension
05/25
05/25
NCT05221281: Implementing a Multimodal RCT Intervention to Improve the Transition of Patients With Crohn's Disease From Pediatric to Adult Care

Active, not recruiting
N/A
90
Canada
Multimodal intervention consisting of four core components, Standard of care, Control
The Hospital for Sick Children, Crohn's and Colitis Canada, The Leona M. and Harry B. Helmsley Charitable Trust, The Canadian Children Inflammatory Bowel Disease Network: A Partnership with the CH.I.L.D. Foundation, The CH.I.L.D. Foundation - Children with Intestinal & Liver Disorders
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Adolescent Development, Transition, Mental Health Wellness 1
07/25
12/25
CIDsCaNN, NCT02308917: The Canadian Children Inflammatory Bowel Disease Network

Recruiting
N/A
2400
Canada
The Hospital for Sick Children, Children's Hospital of Eastern Ontario, British Columbia Children's Hospital, Alberta Children's Hospital, Stollery Children's Hospital, IWK Health Centre, Montreal Children's Hospital of the MUHC, St. Justine's Hospital, Health Sciences Centre, Winnipeg, Manitoba, Eastern Health, Children's Hospital of Western Ontario, McMaster Children's Hospital
Inflammatory Bowel Diseases, Crohn's, Ulcerative Colitis
04/26
04/26
Fujii, Toshimitsu
NCT02332356: Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease

Active, not recruiting
3
100
Japan
azathioprine or adalimumab and infliximab
Tokyo Medical and Dental University
Crohn Disease
03/24
03/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Shimizu, Masaki
NCT05814159: A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

Active, not recruiting
3
15
Japan
Anakinra, Kineret, Placebo
Swedish Orphan Biovitrum, CMIC Co, Ltd. Japan
Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
12/25
06/26
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
04/26
05/26
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
Nagahori, Masakazu
NCT04701411 / 2020-003193-48: A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease

Recruiting
3
20
Europe, Japan, RoW
Darvadstrocel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
06/25
12/25
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting
3
150
Europe, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
07/30
07/30
Kawamoto, Ami
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27

Download Options